“The breadth of data that is being presented at ABA 2025 reflects our commitment to improving patient outcomes,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “With more than ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The phase ...

March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE ® trial of ...

“The breadth of data that is being presented at ABA 2025 reflects our commitment ... Randomized Control Trial Evaluating PermeaDerm A randomized multicenter trial comparing PermeaDerm to a ...

(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage immunology company, Tuesday announced that it is presenting findings from its MINDFuL Phase II trial at ... Preliminary data showed 69.2% ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

In the dynamic environment of biotechnology trials, the significance of Clinical Data Management systems (CDMs) cannot be overstated. As we navigate the complexities of these trials and the ...

In today’s pharmaphorum podcast, Orr Inbar, co-founder and CEO of QuantHealth, a Tel Aviv-based AI-powered clinical trial design company, discusses how advances in data and AI can help.

OAKLAND (Reuters) - - Billionaire Elon Musk's lawsuit against OpenAI will go to a jury trial in spring 2026, the federal judge presiding over the case decided on Friday. Last month, OpenAI and ...